Increased use of GLP-1 drugs has led to market saturation and overwhelmed poison centers.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Increased use of GLP-1 drugs has led to market saturation and overwhelmed poison centers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
- Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.